A Tiny Bacterium With A Big Impact: Revisiting The Role Of Helicobacter Pylori In Gastrointestinal Diseases - An Editorial

H N Sarker[1]

For many decades the human stomach was believed to be sterile because of its highly acidic environment. This belief was challenged in 1982 when Barry Marshall and Robin Warren demonstrated the presence of *H. pylori* in patients with chronic gastritis, fundamentally changing the understanding of gastrointestinal disease pathogenesis [1]. Their work established a clear link between chronic bacterial infection and several major gastrointestinal disorders. The discovery of Helicobacter pylori revolutionised modern gastroenterology.

Today, *H. pylori* infection is recognised as one of the most common chronic bacterial infections worldwide, affecting nearly half of the global population [2]. The prevalence is considerably higher in low- and middle-income countries, where socioeconomic factors such as overcrowding, poor sanitation, and limited access to healthcare facilitate transmission [2]. Although many infected individuals remain asymptomatic, the bacterium persists within the gastric mucosa and induces chronic inflammation that may lead to clinically significant disease [3].

Chronic gastritis represents the most consistent pathological outcome of *H. pylori* colonisation. Persistent infection leads to infiltration of inflammatory cells within the gastric mucosa, resulting in long-standing mucosal injury and structural changes [3]. Over time, this inflammatory process may progress through a cascade of pathological events, including atrophic gastritis and intestinal metaplasia, both of which are recognised precursors of gastric malignancy [4]. Thus, the presence of *H. pylori* marks the beginning of a disease spectrum that may evolve over several decades.

Among the various gastrointestinal disorders associated with *H. pylori*, peptic ulcer disease remains the most widely recognised. The bacterium is responsible for the majority of duodenal ulcers and a significant proportion of gastric ulcers worldwide [5]. Infection disrupts mucosal defence mechanisms, alters gastric acid secretion, and promotes mucosal inflammation, ultimately leading to ulcer formation [5]. Importantly, eradication therapy significantly reduces ulcer recurrence, emphasising the causal relationship between the organism and the disease process.

Beyond ulcer disease, the association between *H. pylori* and gastric cancer represents one of the most important discoveries in infection-related oncology. The World Health Organization has classified *H. pylori* as a class I carcinogen, reflecting compelling evidence linking chronic infection to gastric adenocarcinoma [6]. Long-standing inflammation induced by the bacterium promotes genetic instability and mucosal transformation, increasing the risk of malignant progression [4]. Epidemiological studies suggest that individuals infected with *H. pylori* have a two- to three-fold higher risk of developing gastric cancer compared with uninfected individuals [6].

Another notable malignancy associated with *H. pylori* infection is gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Chronic antigenic stimulation by the bacterium leads to proliferation of lymphoid tissue within the gastric mucosa, which may eventually transform into lymphoma [3]. Remarkably, early-stage gastric MALT lymphoma often regresses after successful eradication of *H. pylori*, providing strong evidence of a direct pathogenetic link [3].

Despite decades of research, the clinical outcomes of *H. pylori* infection vary widely among individuals. Only a minority of infected persons develop severe disease, suggesting that host genetic factors, bacterial virulence determinants, and environmental influences collectively determine disease susceptibility [4]. Virulence factors such as cytotoxin-associated gene A (CagA) and vacuolating cytotoxin A (VacA) strains have been associated with more severe gastric inflammation and a higher risk of malignancy [4].

In recent years, new challenges have emerged in the management of *H. pylori* infection. Increasing antibiotic resistance threatens the effectiveness of conventional eradication regimens and complicates treatment strategies [5]. Consequently, updated therapeutic guidelines increasingly emphasise region-specific antibiotic selection and susceptibility-guided therapy. Moreover, expanding knowledge of the gastric microbiome has prompted further investigation into the complex interactions between *H. pylori*, other microorganisms, and the host immune system.

More than four decades after its discovery, *Helicobacter pylori* continues to influence both clinical practice and biomedical research. The bacterium exemplifies how a seemingly small microbial pathogen can exert profound effects on human health. Strengthening strategies for early detection, effective eradication, and prevention may significantly reduce the global burden of gastrointestinal diseases linked to this organism. Addressing the challenges posed by *H. pylori* therefore remains an important priority for clinicians, researchers, and public health systems worldwide.

1. *Professor (Ex), Medicine, Sher-E-Bangla Medical College, Barishal, and Sheikh Sayera Khatun Medical College, Gopalganj, Bangladesh (ORCID: 0000-0001-6523-9395)*

Received: 12 Mar 2026
Published Online: 18 Mar 2026
DOI: 10.5281/zenodo.19496976

Volume: 9, Number: 2, Page: 1-1
e-ISSN: 2789-5912
ISSN: 2617-0817

REFERENCE

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–1315.
2. Hooi JKY, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153:420-429.
3. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut. 2017;66:6-30.
4. Polk DB, Peek RM. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010;10:403-414.
5. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175-1186.
6. International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC Monographs. 1994;61:1-241.